Conclusion
Temperature controlled high power short duration ablation with 90watts
for 4 seconds for PVI using the QDot catheter lead to a short procedure
and RF time with no major complications in this trial. Despite optimized
temperature control and power adjustment, steam pops not leading to
clinical implications like tamponade or neurological deficits occurred
in 39% of patients. The different amount of steam pops compared to
initial trials maybe due to the used ablation generator.
References:
[1] Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L,
Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK,
Nielsen JC, Curtis AB, Davies DW, Day JD, d’Avila A, de Groot N, Di
Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst
S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek
E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH,
Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M,
Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K,
Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling
R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T: 2017
HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and
surgical ablation of atrial fibrillation. Heart Rhythm 2017;
14:e275-e444.
[2] Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S,
Arentz T, Deisenhofer I, Veenhuyzen G, Scavee C, Jais P, Puererfellner
H, Levesque S, Andrade JG, Rivard L, Guerra PG, Dubuc M, Thibault B,
Talajic M, Roy D, Nattel S, investigators At: Adenosine-guided pulmonary
vein isolation for the treatment of paroxysmal atrial fibrillation: an
international, multicentre, randomised superiority trial. Lancet 2015;
386:672-679.
[3] Anter E, Contreras-Valdes FM, Shvilkin A, Tschabrunn CM,
Josephson ME: Acute pulmonary vein reconnection is a predictor of atrial
fibrillation recurrence following pulmonary vein isolation. J Interv
Card Electrophysiol 2014; 39:225-232.
(4) Kottmaier M, Popa M, Bourier F, Reents T, Cifuentes J, Semmler V et
al. Safety and outcome of very high power short duration ablation using
70 Watts for pul- monary vein isolation in patients with paroxysmal
atrial fibrillation. Europace 2019; doi: 10.1093/europace/euz342.
[5] Leshem E, Zilberman I, Tschabrunn CM, Barkagan M,
Contreras-Valdes FM, Govari A, Anter E: High-Power and Short-Duration
Ablation for Pulmonary Vein Isolation: Biophysical Characterization.
JACC Clin Electrophysiol 2018; 4:467-479.
(6) . Yavin H, Leshem E, Shapira-Daniels A, et al. Impact of high-power
short-duration radio- frequency ablation on long-term lesion durability
for atrial fibrillation ablation. J Am Coll Cardiol EP 2020;6:973–85.
(7) Reddy VY, Grimaldi M, De Potter T, Vijgen JM, Bulava A, Duytschaever
MF, Martinek M, Natale A, Knecht S, Neuzil P, Pürerfellner H. Pulmonary
Vein Isolation With Very High Power, Short Duration,
Temperature-Controlled Lesions: The QDOT-FAST Trial. JACC Clin
Electrophysiol. 2019 Jul;5(7):778-786.
[8] Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman
JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J,
Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de
Feyter PJ, Vahanian A, Topol EJ, Investigators R-: Bivalirudin and
provisional glycoprotein IIb/IIIa blockade compared with heparin and
planned glycoprotein IIb/IIIa blockade during percutaneous coronary
intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863.
[9] Kottmaier M, Bourier F, Pausch H, Reents T, Semmler V,
Telishevska M, Koch-Buttner K, Lennerz C, Lengauer S, Kornmayer M,
Rousseva E, Brooks S, Brkic A, Ammar-Busch S, Kaess B, Dillier R,
Grebmer C, Kolb C, Hessling G, Deisenhofer I: Safety of Uninterrupted
Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent
Left Atrial Catheter Ablation Procedures. Am J Cardiol 2018;
121:445-449.
(10) Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S,
Arentz T, Deisenhofer I, Veenhuyzen G, Scavee C, Jais P, Puererfellner
H, Levesque S, Andrade JG, Rivard L, Guerra PG, Dubuc M, Thibault B,
Talajic M, Roy D, Nattel S and investigators At. Adenosine-guided
pulmonary vein isolation for the treatment of paroxysmal atrial
fibrillation: an international, multicentre, randomised superiority
trial. Lancet . 2015;386:672-9.
(11) Bourier F, Duchateau J, Vlachos K, Lam A, Martin CA, Takigawa M,
Kitamura T, Frontera A, Cheniti G, Pambrun T, Klotz N, Denis A, Derval
N, Cochet H, Sacher F, Hocini M, Haissaguerre M, Jais P: High-power
short-duration versus standard radiofrequency ablation: Insights on
lesion metrics. J Cardiovasc Electrophysiol 2018.
(12) Deneke T, Halbfaß P, Pürerfellner H. High-power short duration
ablation for pulmonary vein isolation: simply cranking up the energy?
Europace. 2020 Mar 1;22(3):335-337
(13) Deneke T, Jais P, Scaglione M, Schmitt R, DI Biase L, Christopoulos
G, Schade A, Mügge A, Bansmann M, Nentwich K, Müller P, Krug J, Roos M,
Halbfass P, Natale A, Gaita F, Haines D. Silent cerebral events/lesions
related to atrial fibrillation ablation: a clinical review. J Cardiovasc
Electrophysiol. 2015 Apr;26(4):455-463
(14) Takigawa M, Kitamura T, Martin CA, Fuimaono K, Datta K, Joshi H,
Constantin M, Bourier F, Cheniti G, Duchateau J, Pambrun T, Denis A,
Derval N, Sacher F, Cochet H, Hocini M, Haïssaguerre M, Jaïs P.
Temperature- and flow-controlled ablation/very-high-power short-duration
ablation vs conventional power-controlled ablation: Comparison of focal
and linear lesion characteristics. Heart Rhythm. 2021 Apr;18(4):553-561.